Clinical Trial Update: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 study of IMM-6-415 in Ras/RAF-mutant solid tumors, including pancreatic adenocarcinoma, non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma

Drugs mentioned

• IMM-6-415

Snippet

Sponsor: Immuneering Corporation | Conditions: Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED